Aura Biosciences reports positive retrospective data for AU-011 in choroidal melanoma vs. radiotherapy

Aura Biosciences, Inc.

Belzupacap sarotalocan showed statistically significant vision preservation at 2 years vs. plaque radiotherapy (logMAR p=0.0094).
Radiotherapy patients lost ≥3 lines of vision in a majority by 2 years; ≥6 lines by 3 years.
Data from 43 AU-011 patients vs. 150 matched radiotherapy controls (tumor edge within 3.0 mm of fovea).
Mean follow-up for AU-011 was 15.6 months; study is retrospective and hypothesis-generating.
Phase 2 trial (suprachoroidal) ongoing; pivotal trial expected to initiate by end of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.